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TISSUE FACTOR and PLATELETS
1-
Leukocyte contamination 
in platelet RNA preparations
2-
IT’S TIME TO TAKE STOCK OF…..
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To the editor:
No evidence for tissue factor on platelets
Beth A. Bouchard
Department of Biochemistry, University of Vermont College of Medicine,
Burlington, VT
Kenneth G. Mann
Department of Biochemistry, University of Vermont College of Medicine,
Burlington, VT
Saulius Butenas
Department of Biochemistry, University of Vermont College of Medicine,
Burlington, VT
…..to resolve this ONGOING CONTROVERSY….
…. platelets express active TF after de novo synthesis,2,3 transfer from monocytes,4
or release from -granules.5
In other studies,6,7 however, the existence of platelet TF could not be demonstrated.
2. Panes O et al. Human platelets synthesize and express functional tissue 
factor. Blood. 2007
3. Schwertz H, et al. Signal-dependent splicing of tissue factor pre-mRNA 
modulates the thrombogenicity of human platelets. J Exp Med. 2006
4. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing 
thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand1 
and platelet P-selectin. J Exp Med. 2003
5. Siddiqui FA et al. The presence and release of tissue factor from human 
platelets. Platelets. 2002
6. Butenas S, et al. Tissue factor activity in whole blood. Blood. 2005.
7. Osterud B et al. What is blood borne tissue factor? Thromb Res. 2009.
2Flow cytometric analyses indicated that no TF was expressed by PAR1- and PAR4-
activated platelets compared with unactivated platelets  despite maximal -granule 
release (98% P-selectin–positive platelets)….
…no TF antigen was detected by immunoassay after prolonged stimulation of 
platelets with LPS.
No FXa was generated by extrinsic FXase using unstimulated or stimulated platelets 
as a possible TF source. Similarly, no clot was formed in a plasma-based clotting 
assay.
TF on monocytes or monocyte-derived microparticles is not transferred to platelets.
RESULTS:
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Based on these observations, we conclude that platelets do not express detectable 
TF antigen or activity. 
Discrepancies between our data and those published by others may be a result of 
the assays used to quantify TF antigen and activity in different laboratories. 
Our assays use specific and highly sensitive anti-TF monoclonal antibodies and 
physiologically relevant standards and controls, whereas other reported assays use 
combinations of monoclonal and polyclonal antibodies, which may recognize TF 
fragments or cross-react with other proteins…..
CONCLUSION:
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? ? ? ?
METHODS in figure legend:
BLOOD, 5 AUGUST 2010  VOLUME 116, NUMBER 5
Figure 1. Search for TF on platelets by flow cytometry. (A) Washed platelets were 
activated with PAR1 (100µM) and PAR4 (500 µM) agonist peptides (2 hours, 
37°C). (B) Platelet-rich plasma was incubated with THP-1 cells in the presence or absence of 
250 ng/mL LPS (4 hours, 37°C)……
Eureka! ! ! !
To the Editor:
Tissue factor expression on platelets is a dynamic event
Marina Camera
Dept. of Pharmacological Sciences, Univ. degli Studi di Milano and Centro Cardiologico Monzino IRCCS, Milan
Marta Brambilla
Centro Cardiologico Monzino IRCCS, Milan
Vincenzo Toschi
Division of Haemat and Blood Transfusion and Thrombosis Centre, AO Ospedale San Carlo Borromeo, Milan
Elena Tremoli
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3RESULTS:
Our results confirm that the amount of TF present on the platelet surface, after 2 hours stimulation with PAR-1
agonist peptide and TRAP-6, is negligible (..) (Figure 1). After a 15 minutes stimulation, however, PAR-1 and
TRAP-6 significantly increase platelet TF expression (..) compared with resting platelets (...)
• This indicates that TF expression by platelets in response to certain agonists is an 
early event, confirming data already published by our group2,3.
(REF: Camera et al, ATVB 2003 and ATVB 2008)
CONCLUSION:
• Our data support the evidence that platelets do express TF as a result of a rapid 
and dynamic process. Thus its detection may considerably vary if observed at 
different time points after in vitro cell stimulation.
Oggetto: Decision on your Letter to the Editor #BLOOD/2010/307306
Title: Tissue factor expression on platelets is a dynamic event
Dear Dr. Camera:
I am pleased to inform you that your Letter to the Editor has been accepted for
publication in the next available issue of Blood Journal.
…………..
Sincerely, 
Cynthia E. Dunbar, M.D.
Editor-in-Chief, Blood
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4Manuscript Number: TR-D-10-00225R1
Gene expression profiling reveals multiple 
differences in platelets from patients with stable 
angina or non-ST elevation acute coronary 
syndrome
Gualtiero Colombo, Karl Gertow, Giancarlo Marenzi, Marta Brambilla, Monica De Metrio,
Elena Tremoli and Marina Camera
Centro Cardiologico Monzino IRCCS; Department of Pharmacological
Sciences, Università degli Studi di Milano, Milan, Italy
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“The biggest challenge with platelet RNA WGE studies is the 
contamination with leukocyte RNA. The RNA content of a single leukocyte is 
estimated to be 3-4 log higher than that of a platelet.  The authors are aware of this 
drawback and comment on this several times.  They have chosen an arbitrary limit for 
leukocyte contamination with not more than 5 leucocytes per 105 platelets.  This is a 
rather liberal limit and the results of Q-PCR tests with myeloid and lymphoid markers 
have not been shown (bottom of page 8).  There are other means to inspect platelet 
WGE studies for signals that have been produced by RNA from contaminating 
leucocytes.
Each blood cell type has its own set of "strictly lineage-specific transcripts" and these 
could have been used to provide reassurance that leukocyte contamination is low 
enough to not be a confounding factor in the analysis.”
Reviewer comment:
Methods – Platelet isolation
•40 ml blood in ACD/patient
•Platelet isolation by sequential
centrifugation of PRP (top third) with
PGE1 and EDTA
• Assessment of platelet activation (FACS)
• Assessment of leukocyte contamination
• RNA extraction and quality control
Top
third
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Leukocyte population markers
5Granulocytes
Monocytes
Limphocytes
Set the quadrant Open in G1
Only preparations with less than 5 leukocytes/105 platelets were used for RNA isolation
Assessment of leukocyte contamination by flow cytometry
G1
1.3 (29%)0.6 (24%)1.3 (35%)
0 (71%)0 (76%)0 (65%)
NSTE-ACS patients
1 (24%)1 (24%)2.4 (30%)
0 (76%)0 (76%)0 (70%)
Stable angina patients
Lymphocytes
(CD2+ + CD20+)
Monocytes
(CD14+)
Granulocytes (CD66b+)
Mean number of contaminating WBC in 105 platelets, (% of patients)
Platelet Preparations used for Microarray, PCR and Western blot experiments
Mean number of contaminating WBC in 105 platelets
0.7 (100%)2.5 (67%)5.2 (100%)
0 (0%)0 (33%)0 (0%)
NSTE-ACS patients
1.7 (64%)0.8 (38%)5.6 (100%)
0 (38%)0 (64%)0 (0%)
Stable angina patients
Lymphocytes
(CD2+ + CD20+)
Monocytes
(CD14+)
Granulocytes (CD66b+)
Mean number of contaminating WBC in 105 platelets, (% of patients)
Discarded Platelet Preparations
1.3 (29%)0.6 (24%)1.3 (35%)
0 (71%)0 (76%)0 (65%)
NSTE-ACS patients
1 (24%)1 (24%)2.4 (30%)
0 (76%)0 (76%)0 (70%)
Stable angina patients
Lymphocytes
(CD2+ + CD20+)
Monocytes
(CD14+)
Granulocytes (CD66b+)
Mean number of contaminating WBC in 105 platelets, (% of patients)
Platelet Preparations used for Microarray, PCR and Western blot experiments
Mean number of contaminating WBC in 105 platelets
ImageStreamx: multispectral imaging flow cytometer (AMNIS)
“By combining the speed, sensitivity, and phenotyping abilities of flow cytometry with 
the detailed imagery and functional insight of microscopy, the ImageStreamX
overcomes the limitations of both techniques (…)”
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SSC FITC PE PerCPBF
lymphocytes
CD3-20 PE
SSC FITC PE PerCPBF
granulocytes
CD66 FITC
SSC FITC PE PerCPBF
FILTRI Purecell PL 
(PALL)
- Standardization
-Time
- Platelet recovery
- Efficiency of leukocyte removal
- Cost
- Aggregates removal
NI
1 hour
400 x106
<5 leuko /105 plt
1 euro/each
NO
YES
30 min
500 x106
<5 leuko /105 plt
18.40 euro/each
YES
Tyrode buffer Purecell filter
Cell sorting NOZZLE
PRESSIONE
MASCHERA
20.000 ev/sec
GATING STRATEGY
- Frequence: 78,1
- Drop 1: 260
- Gap: 8
- Drop Delay: 36,24
- Voltage plate: 6000 
THRESHOLD
70 μm
70 PSI
0 32 0
100 mil ev/ ~2ore
7LEUKOCYTE CONTAMINATION
Granulocyte gate (CD45+/CD66+): 0 events
Limphocyte gate (CD45+/CD20+/CD3+): 0 events
Monocyte gate (CD45+/CD14+): 0 events
- Standardization
- Blood volume
- Time
- Platelet recovery
- Efficiency of leukocyte removal
- Cost
- Specialized technician
NI
30 ml
1 hour
700 x106
<5 leuko /105 plt
1 euro
NO
YES
5 ml
3 hours
100 x106
0 leuko /105 plt
>100 euro
YES
Tyrode buffer Sorting
CELL SORTING vs WASHING PROCEDURE
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NO GP IIbIIIa activation
but
degranulation
POST-SORTING 
platelet activation
Platelet RNA
Assessment of platelet RNA quality
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8RT-PCR
Leukocyte  contamination of the platelet RNA preparations was assessed by 
amplification of specific markers for T- and B-lymphocytes (CD2 and CD20, 
respectively), monocytes (CD14), granulocytes (CD66b), and pan-leukocytes (CD45) by 
RT-PCR.
Platelet isolation
Assessment of platelet activation (FACS)
Assessment of leukocyte contamination
RNA extraction and quality control
Microarray experiments
Microarray experiments
No PBMC signal was detected in PLT preparations
SYMBOL Gene 1 2 3 4 5 6 7 8 9 1 2 PLTavg PBMCavg
CD14 CD14 177,37 127,28 173,98 160,45 135,79 246,94 116,53 238,39 294,25 32191,74 30427,67 185,66 31309,71
DUSP1 dual specificity phosphatase 1 71,62 86,98 122,31 106,37 102,45 111,64 102,94 171,63 274,06 21102,30 23133,63 127,78 22117,97
FCN1 ficolin 135,49 123,21 187,48 151,90 129,41 216,99 126,45 289,58 418,81 25122,01 28195,81 197,70 26658,91
HLA‐DRB4 HLA‐DRB4 153,01 116,47 174,56 127,97 115,80 181,80 128,24 178,44 429,92 22961,42 18029,95 178,47 20495,69
ITGB2 integrin, beta 2 (antigen CD18 (p95) 189,66 132,15 202,59 155,13 126,41 205,24 125,22 328,13 527,22 27826,67 32995,37 221,31 30411,02
LYZ lysozime 361,70 156,90 440,73 154,19 200,61 353,89 256,93 408,17 689,61 51601,36 51003,24 335,86 51302,30
Background value=100
Positive signal threshold: at least 3 times the background value.
PLATELETS PBMC
Highest PBMC expressed genes defined as signal intensity > 20000: 227
Excuse me!!
Have you seen
a leukocyte?
